A Prognostic Model Based on PAM50 and Clinical Variables (PAM50MET) for Metastatic Hormone Receptor-positive HER2-negative Breast Cancer.
Aleix PratYi-Hsuan TsaiTomás PascualLaia ParéBarbara AdamoMaría Jesús Vidal LosadaFara Brasó-MaristanyPatricia GalvánJan Christoph BraseVanessa Rodrik-OutmezguineStephen JohnstonEva Ciruelos GilJoel S ParkerPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
PAM50MET is prognostic in HR+/HER2- MBC, and further evaluation might help identify candidates for endocrine therapy only or novel therapies.